News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

GlobalData Release: Taiwan's Healthcare Market Boosted by Aging Population

9/4/2012 11:55:42 AM

LONDON, UK (GlobalData), 3 September 2012 - Although a challenge for the national government, a growing aging population combined with the country’s universal healthcare system means that Taiwan’s healthcare market can expect to expand in the future, says the latest report by industry experts GlobalData.

According to the latest study*, Taiwan’s pharmaceutical industry is predicted to climb from a $3.8 billion valuation in 2011 to $4.8 billion by 2020, while the medical devices industry is expected to reach $3 billion by the end of the decade from a 2011 valuation of $1.9 billion.

GlobalData’s report states that the country’s aging population will be an important factor in driving this growth, with just under 11% of Taiwan’s residents above the age of 65 last year. Taiwan’s population increased slightly between 2005 and 2010, from 22.8 million to 23.2 million, but this growth was mainly down to a longer national life expectancy, as the birth rate fell from 9.1 per 1,000 population in 2005 to 7.2 per 1,000 population in 2010.

Taiwan’s over-65 population will expand still further, states GlobalData, accounting for 13% of the country’s people by 2020. Correspondingly, Taiwan’s disease burden is forecast to increase, placing greater strain on the National Health Insurance (NHI) system and its commitment to universal healthcare. According to Taiwan’s Department of Health (DoH), healthcare expenditure as a percentage of Gross Domestic Product (GDP) will climb from 6.6% in 2011 to 7.2% by 2020. However, despite Taiwan’s compulsory insurance policy, out-of-pocket expenditure in the country is high, representing 36.4% of total health spending in 2010.

* Healthcare, Regulatory and Reimbursement Landscape - Taiwan

This report identifies the key trends in the Taiwan healthcare market and provides insights into the demographic, regulatory and reimbursement landscape and healthcare infrastructure.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.


GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For more information, please contact our Press Office on +44 (0)1204 543 528 or at

Read at

comments powered by Disqus